Evelo Biosciences, Inc. presented preclinical data for EDP1867, a non-live pharmaceutical preparation of a single strain of Veillonella parvula, at ECTRIMS 2021, October 13-15, 2021. The data show that orally administered EDP1867 reduced disease severity and incidence of relapse in relapsing-remitting experimental autoimmune encephalomyelitis (EAE) mouse models of multiple sclerosis (MS), supporting the development of EDP1867 for the treatment of neuroinflammatory diseases. In the preclinical study presented at ECTRIMS, EDP1867 was tested in a relapsing-remitting EAE mouse model of neuroinflammation. Oral daily treatment with EDP1867 administered prophylactically or therapeutically reduced the severity of disease as demonstrated by a decreased mean maximum score and a decreased incidence of relapse compared to placebo. Treatment with EDP1867 reduced inflammation and demyelination in the spinal cord as shown in histopathological analysis. Transcriptional profiling of small intestine tissue confirmed that EDP1867 upregulated genes in lymphocyte pathways that resolve inflammation, as well as genes associated with intestinal homeostasis. EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor. It is made non-live by ?-irradiation in the manufacturing process making it unable to colonize or persist in the gut, a central feature of SINTAX medicines. EDP1867 is currently in clinical development. It has the potential to treat a wide range of inflammatory and neuroinflammatory diseases.